Karachi: Otsuka Pakistan Limited (OPL), a key player in the pharmaceutical and nutraceutical sectors, presented its annual Corporate Briefing Session for the fiscal year 2023-24 on October 30, 2024. The company disclosed a series of financial details, strategic shifts, and future outlooks, aiming to navigate through an increasingly volatile market environment.

According to information available from the Pakistan Stock Exchange (PSX), OPL reported a modest growth in sales, achieving a total revenue of Rs. 3.16 billion in 2024, up from Rs. 3.04 billion in 2023. However, there was a noticeable decline in profitability with gross profit falling to Rs. 577 million in 2024 from Rs. 644 million in 2023. The operating profit also saw a drastic reduction to Rs. 122 million from Rs. 36 million over the same period.

In response to the challenging economic conditions, OPL has made strategic adjustments by rationalizing its IV solutions sector while increasing focus on its Clinical Nutrition (CN) and Pharmaceutical Nutrition (PN) segments. This included the launch of new nutraceutical products such as AlphaBerry, aimed at enhancing urinary tract health, which has received positive market feedback. Moreover, a significant reshuffling in distribution channels, particularly in Southern Pakistan, has been implemented to improve profitability and cash flow.

The company also highlighted several operational developments, including deregulation impacts and anticipated price adjustments due to increased costs linked to global oil prices, local inflation, and currency depreciation. OPL emphasized its commitment to maintaining affordability despite these challenges.

Looking ahead, OPL's strategy involves further diversification of its product line, focusing on high-margin clinical and nutraceutical products. This plan is backed by investments in staff development programs to boost productivity and product quality, thereby reinforcing its market position and shareholder value amidst economic pressures.